title: [Combination chemotherapy of mitomycin C and cytosine arabinoside in the intravesical treatment for superficial bladder tumors: report 2. Evaluation of prophylactic intravesical infusion therapy].
abstract: Combined chemotherapy of Mitomycin C (20 mg to 30 mg) and Cytosine Arabinoside (200 mg) was given by intravesical infusion to 25 patients with superficial bladder tumor who underwent transurethral treatment for prevention of postoperative recurrence. The prophylactic effect of this therapy was evaluated as follows. 1) The postoperative recurrence rates by the actuarial method were 4.0% in six months, 8.1% in one year, 22.2% in two years, 37.4% in three years and 37.4% in five years. 2) The prophylactic effect on recurrence tended to be marked on primary tumors, solitary tumors, low grade tumors and relatively large tumors. 3) The correlation of doses and the recurrence rate was significantly observed: prophylactic effect tended to increase in proportion to increase of doses of both Mitomycin C and Cytosine Arabinoside.
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011184:Postoperative Period; D001743:Urinary Bladder / Q000601:surgery; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery
chemical_list: D008937:Mitomycins; D003561:Cytarabine; D016685:Mitomycin